Building on a Proven Platform

With an eye on the future™

our retinal disease–focused pipeline is designed to provide solutions for patients. When it comes to matters of sight, innovation is our vision.

We intend to keep transforming the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema.

EYP-1901: Twice-Yearly Anti-VEGF Treatment

The Need

Currently, patients with wet AMD still lose their vision over time, despite regular anti-VEGF therapy, due to undertreatment and adherence challenges.

The EYP-1901 solution = Durasert® + Vorolanib

Twice Yearly Intravitreal delivery of vorolanib using a bioerodible formulation of Durasert®

Vorolanib: A validated TKI that has shown efficacy in wet AMD. Blocks all 3 isoforms of VEGFR, the main driver of the proliferation of blood vessels that are the hallmark of wet AMD

EYP-1901 is designed to provide steady blocking of VEGFR to prevent neovascularization and loss of vision

With EYP-1901, a solution is possible through sustained, stable release that may lead to better visual outcomes